Sam Tomioka, MS

Executive Director, Head of Computational Research and Analytics
Sumitomo Pharma America, Inc.

Poster(s):

• (192) Real-world characteristics of patients with overactive bladder initiating vibegron or mirabegron
  Wednesday, October 29, 2025